retatrutide phase 2 nejm 2023 obesity trial jastreboff Meets Weight Loss Endpoints in 3 Retatrutide: FDA approval time, trial

The Wolverine stack is for the David Protein boys in pursuit of muscle growth and repair

See How Peakstack Is Changing Lives GLP-1s just the start

By targeting GLP-1 receptors in the pancreas, stomach, and brain, Ozempic can stimulate insulin release, lower blood sugar levels, and consequently prevent excess glucose from being stored as fat which can result in weight loss

The SELECT trial, published in the New England Journal of Medicine , found that semaglutide, known by the brand name Ozempic, significantly reduced the risk of heart attacks and strokes in people with obesity and established cardiovascular disease